Floatz logo

Pertuzumab

Colon Carcinoma

IFOM ETS - The AIRC Institute of Molecular Oncologymonoclonal_antibodyPhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

153 Active assets in the Colon Carcinoma cohort.

Asset / SponsorPhaseRating
Floxuridine
City of Hope Medical Center
Phase 2BBB
Fluorouracilum
Akeso
Phase 4BB
Xaliplatin
Sun Yat-sen University
Phase 3BB
Irinotecan
SCRI Development Innovations, LLC
Phase 3BB
TRASTUZUMAB
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Pertuzumab is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 3
75 / 100
View asset →
inflammatory breast carcinomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →
breast cancerActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →